4:41 PM
 | 
May 30, 2007
 |  BC Extra  |  Top Story

Schering-Plough in-licenses Asentar

Novacea (NOVC) jumped $6.94 (86%) to $15 on 21.2 million shares on Wednesday after granting SGP exclusive worldwide rights to develop and commercialize Asentar (DN-101)...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >